The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
暂无分享,去创建一个
J. Reis-Filho | L. Norton | B. Weigelt | M. Robson | O. Ceyhan-Birsoy | N. Riaz | S. Powell | J. Setton | David N. Brown | D. Mandelker | X. Pei | H. Wen | P. Selenica | Rahul Kumar | Sasi Arunachalam
[1] Rui Bi,et al. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. , 2018, Journal of the National Cancer Institute.
[2] Martin A. M. Reijns,et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.
[3] Sitao Wu,et al. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA Oncology.
[4] J. Reis-Filho,et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.
[5] P. Kantoff,et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.
[6] Nancy R. Zhang,et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers , 2017, Nature Communications.
[7] E. Lander,et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.
[8] I. Papasotiriou,et al. Current perspectives on CHEK2 mutations in breast cancer , 2017, Breast cancer.
[9] E. Birney,et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.
[10] A. Whittemore,et al. Genetic modifiers of CHEK2*1100delC associated breast cancer risk , 2016, Genetics in Medicine.
[11] Michael Jones,et al. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[13] J. Martens,et al. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas , 2015, BMC Cancer.
[14] J. Reis-Filho,et al. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. , 2015, Journal of the National Cancer Institute.
[15] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[16] Lihong Liu,et al. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. , 2013, DNA and cell biology.
[17] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[18] Chuan Liu,et al. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[19] Yajie Wang,et al. The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[20] S. Bojesen,et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Kenneth Offit,et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. , 2005, Human molecular genetics.